CD274 and neoplasm: Additionally, combination of 64Cu-based targeted radionuclide therapy using the αvβ3 integrin-targeted 64Cu-DOTA-EB-cRGDfK (925 MBq/kg) with programmed death-ligand 1 (PD-L1)-based immunotherapy using αPD-L1 mAb (10 mg/kg) has been tested in an MC38 tumour model and resulted in a significant delay in tumour growth [40].